FLT1 binding proteins and methods of use

TW202639588APending Publication Date: 2026-10-01AMGEN INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW114137227
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-10-28
Filing Date
2025-09-26
Publication Date
2026-10-01

Smart Images

  • Figure TWG2TA001078319_001
    Figure TWG2TA001078319_001
  • Figure TWG2TA001078319_002
    Figure TWG2TA001078319_002
  • Figure TWG2TA001078319_003
    Figure TWG2TA001078319_003
Patent Text Reader

Abstract

Provided herein are FLT1 binding proteins, as well as related nucleic acids, vectors, host cells, pharmaceutical compositions and kits. The present disclosure additionally provides methods of treating a subject in need thereof, including subjects in need of treatment for PAD, CLI, ANOCA, or heart failure (HF). Further provided are methods of increasing VEGF-mediated and / or PlGF-mediated signal transduction in a subject, which, in turn, increases blood flow, capillary density, capillary or coronary growth, and / or cardiac perfusion in the subject. The present disclosure further provides methods of reducing blood pressure and risk of heart failure in a subject. In exemplary embodiments, each of the methods comprise administering to the subject a pharmaceutical composition of the present disclosure. In various embodiments, the pharmaceutical composition comprises a FLT1 binding protein of the present disclosure.
Need to check novelty before this filing date? Find Prior Art